StreetInsider.com News Articles

Form SCHEDULE 13G/A Freenome, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260814/26932384.html

Form SCHEDULE 13G/A Freenome, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260814/26932384.html

Form SCHEDULE 13G Freenome, Inc. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 14 Aug 2026 12:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26927922.html

Form SCHEDULE 13G Freenome, Inc. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 14 Aug 2026 12:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26927922.html

Leerink Starts Freenome Inc. (FRNM) at Outperform

Fri, 14 Aug 2026 06:12:10 -0400

Leerink analyst Puneet Souda initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Outperform rating and a price target of $18.00.

For an analyst ratings summary and ratings history on Freenome Inc. click here. For more ratings news on Freenome Inc. click here.

Shares of Freenome Inc. closed at $11.61 yesterday.

Form 8-K/A Freenome, Inc. For: Jul 20

Thu, 13 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260813/26922887.html

Form 8-K/A Freenome, Inc. For: Jul 20

Thu, 13 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260813/26922887.html

Form SCHEDULE 13G/A Freenome, Inc. Filed by: IPConcept (Luxemburg) S.A.

Wed, 12 Aug 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260812/26914466.html

Form SCHEDULE 13G/A Freenome, Inc. Filed by: IPConcept (Luxemburg) S.A.

Wed, 12 Aug 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260812/26914466.html

Form SCHEDULE 13G/A Freenome, Inc. Filed by: 683 Capital Management, LLC

Wed, 12 Aug 2026 11:13:00 -0400

si-local-file:///var/storage/secattach/20260812/26910928.html

Form SCHEDULE 13G/A Freenome, Inc. Filed by: 683 Capital Management, LLC

Wed, 12 Aug 2026 11:13:00 -0400

si-local-file:///var/storage/secattach/20260812/26910928.html

FDA grants breakthrough device status to Freenome's lung cancer blood test

Wed, 12 Aug 2026 09:00:41 -0400

Freenome, Inc. (Nasdaq: FRNM) announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its investigational SimpleScreen Lung blood-based lung cancer screening test.

The designation covers the proposed use of the test in adults ages 50 to 80 with at least a 20 pack-year smoking history who are not currently participating in guideline-recommended lung cancer screening. The test, ordered by a healthcare provider, is designed to detect early signals of lung cancer from a standard blood draw.

The FDA Breakthrough Devices Program is intended to accelerate the development and review of medical devices for life-threatening or irreversibly debilitating

FDA grants breakthrough device status to Freenome's lung cancer blood test

Wed, 12 Aug 2026 09:00:41 -0400

The FDA Breakthrough Devices Program is intended to accelerate the development and review of medical devices for life-threatening or irreversibly debilitating

FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test

Wed, 12 Aug 2026 09:00:00 -0400

Investigational AI-powered multiomic test is being developed for adults ages 50-80 at high risk who are not currently participating in guideline-recommended lung cancer screening

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to SimpleScreen™ Lung, the company’s investigational lung cancer screening test.

The designation applies to the proposed use of SimpleScreen Lung in adults ages 50 to 80 who have at least a 20 pack-year smoking history and

FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test

Wed, 12 Aug 2026 09:00:00 -0400

Investigational AI-powered multiomic test is being developed for adults ages 50-80 at high risk who are not currently participating in guideline-recommended lung cancer screening

The designation applies to the proposed use of SimpleScreen Lung in adults ages 50 to 80 who have at least a 20 pack-year smoking history and

Form SCHEDULE 13G/A Freenome, Inc. Filed by: BIT Capital GmbH

Wed, 05 Aug 2026 06:27:00 -0400

si-local-file:///var/storage/secattach/20260805/26869660.html

Form SCHEDULE 13G/A Freenome, Inc. Filed by: BIT Capital GmbH

Wed, 05 Aug 2026 06:27:00 -0400

si-local-file:///var/storage/secattach/20260805/26869660.html

Form 4 Freenome, Inc. For: Jul 20 Filed by: Waksal Harlan

Wed, 29 Jul 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260729/26836533.html

Form 4 Freenome, Inc. For: Jul 20 Filed by: Waksal Harlan

Wed, 29 Jul 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260729/26836533.html

Form 3 Freenome, Inc. For: Jul 20 Filed by: Lin Cheng-Ho Jimmy